S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS. (31st January 2022) - Telen, M; Saraf, S; Cruz, K; Idowu, M; Kalfa, T; Osunkwo, I; Hagar, R; Geib, J; Forsyth, S; Schroeder, P; Wu, E; Kelly, P; et al.